Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330525 · ClinicalTrials.gov registry record · Phase 2
Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00330525: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00330525 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 72 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00330525, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
Control of food intake, size and frequency of meals are critical to the development of obesity. The stomach signals feelings of fullness after a meal and therefore plays a role in control of calorie intake. It is unclear whether the approved appetite reducing drug sibutramine changes the function of the stomach. Differences in the way individuals respond to treatment with the appetite suppressant sibutramine may also explain why some people lose weight while others do not. This single center clinical study aims to compare functions of the stomach in healthy, overweight and obese individuals, and to evaluate the effects of the FDA-approved appetite suppressing medication sibutramine on weight loss and stomach functions in patients who are overweight or obese. The effect of individual differences in inherited genes on weight reduction with sibutramine will be tested.
Interventions
- DRUG sibutramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00330525
The ClinicalTrials.gov registry entry for NCT00330525 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sibutramine is the first listed.
NCT00330525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00330525 about?
NCT00330525 is a clinical study titled "Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity". Control of food intake, size and frequency of meals are critical to the development of obesity. The stomach signals feelings of fullness after a meal and therefore plays a role in control of calorie intake. It is unclear whether the approved appetite reducing drug sibutramine changes the function of...
What is the current status of trial NCT00330525?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2005-01. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00330525?
The interventions under investigation include: sibutramine (DRUG).
Who is sponsoring clinical trial NCT00330525?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.